Genentech

Biotechnology company

Based in DC

🤖

AI Overview

With $1.1M in lobbying spend across 32 quarterly filings, Genentech is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2018 to 2025.

$1.1M
Total Spend
8
Years Active
1
Firms Hired
2
Lobbyists Deployed
4
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$120K
2019$120K
2020$120K
2021$120K
2022$140K
2023$160K
2024$160K
2025$160K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Pharmacy, MED

  • HR 4710, 340B Pause Act, and issues relating generally to the 340B Drug Discount Program; issues relating to drug pricing policies.
  • HR 4710, 340B Pause Act and other issues relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and a reimbursement.
  • Prescription Drug User Fee Act reauthorization.
  • issues and legislation relating to 340B drug discount program; issues relating to drug pricing; the Pandemic and All-Hazards Preparedness Act (PAHPA)
  • MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.